TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06058897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye-tracking
Description: Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
Study: NCT06539949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Planning Method (RPM)
Description: RPM is a three day immersive seminar. Subjects will be exposed to a variety of mind-body exercises and psycho educational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
Study: NCT06058897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive exams
Description: Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
Study: NCT06014255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Radical prostatectomy within 4-8 weeks of randomization.
Study: NCT06539949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Journaling
Description: Subjects will be keeping a weekly to-do list.
Study: NCT05078645

Intervention type: DEVICE
Group type: OTHER
Intervention: Maya
Description: The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy

Intervention type: DEVICE
Group type: OTHER
Intervention: Maya
Description: The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
Study: NCT05132335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarkers
Description: One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion
Study: NCT05953584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Participants will receive a stable dose of HU.
Study: NCT06461104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Physical Activity Programme
Description: A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Programme
Description: The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Programme
Description: The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
Study: NCT04931654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: anti-PD-1 and anti-TIM-3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: anti-PD-1 and anti-TIM-3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: anti-PD-1 and anti-TIM-3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: anti-PD-1 and anti-TIM-3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: anti-PD-1 and anti-TIM-3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: anti-PD-1 and anti-TIM-3 bispecific antibody
Study: NCT06582888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: varenicline (target dose 1mg twice daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT06514586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin gel 600 IU . 1mg/g

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl methylcellulose
Description: Placebo
Study: NCT05948917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: The mind-body skills groups consist of supportive small group sessions with about 8-10 participants per group. Participants of these groups learn and practice mind-body techniques including: meditation, self-expression through drawings, autogenics and biofeedback, guided imagery, body awareness, and genograms.
Study: NCT05434897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280 Cream
Description: Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280 Cream
Description: Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280 Cream
Description: Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream
Description: Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
Study: NCT03995004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Sulphate 4mg/1mL
Description: Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Sulphate 4mg/1mL
Description: Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
Study: NCT05895006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alpha-frequency tACS
Description: The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alpha-frequency tACS
Description: The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Random noise stimulation
Description: The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Random noise stimulation
Description: The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
Study: NCT04575402

Intervention type: OTHER
Intervention: Wearable Activity Monitor
Description: Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)

Intervention type: OTHER
Intervention: Wearable Activity Monitor
Description: Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
Study: NCT06043557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drain Placement
Description: Surgical placement of drain based on subject randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drain Placement
Description: Surgical placement of drain based on subject randomization.
Study: NCT06250725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
Study: NCT05446311

Intervention type: DRUG
Intervention: Dinalbuphine sebacate
Description: After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
Study: NCT06562036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
Study: NCT06129292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT group
Description: Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held.
Study: NCT06573918

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EMG-based assessment of paratonia
Description: EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
Study: NCT06481150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Each tablet 30 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05480605

Intervention type: BEHAVIORAL
Intervention: Occupational Therapy
Description: Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
Study: NCT05141045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 PUFA supplement
Description: participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05655494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand-alone Research Portal
Description: The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portal with Virtual Community Health Educator (vCHE)
Description: The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
Study: NCT06215872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercises
Description: Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
Study: NCT06269328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance
Description: For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation anesthesia with sevoflurane for anesthetic maintenance
Description: For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
Study: NCT06215872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercises
Description: Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
Study: NCT06145828

Intervention type: DEVICE
Intervention: Cytokine Adsorption
Description: During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
Study: NCT05322603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)
Description: A decrease in the pain severity (VAS);opioid-sparing effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics
Description: A decrease in the pain severity (VAS)
Study: NCT05949658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 5mg, 10mg, or 15mg once weekly sirolimus
Study: NCT05245968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimitespib
Description: Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimitespib
Description: Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimitespib
Description: Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
Study: NCT05949658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 5mg, 10mg, or 15mg once weekly everolimus
Study: NCT05907044

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RQ3013
Description: 0.15mL/dose containing mRNA 30μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RQ3025
Description: 0.15mL/dose containing mRNA 30μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RQ3027
Description: 0.15mL/dose containing mRNA 30μg
Study: NCT05245968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
Study: NCT05268341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Sentence Builder
Description: computer-assisted treatment program for expressive grammar